Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Income from Continuing Operations: 2022-2025

Historic Income from Continuing Operations for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$30.9 million.

  • Taysha Gene Therapies' Income from Continuing Operations fell 29.62% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 15.66%. This contributed to the annual value of -$84.6 million for FY2024, which is 14.56% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Income from Continuing Operations of -$30.9 million as of Q3 2025, which was down 23.92% from -$24.9 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Income from Continuing Operations high stood at -$15.0 million for Q4 2023, and its period low was -$55.1 million during Q4 2022.
  • For the 3-year period, Taysha Gene Therapies' Income from Continuing Operations averaged around -$21.3 million, with its median value being -$20.1 million (2025).
  • As far as peak fluctuations go, Taysha Gene Therapies' Income from Continuing Operations surged by 72.69% in 2023, and later tumbled by 43.36% in 2024.
  • Taysha Gene Therapies' Income from Continuing Operations (Quarterly) stood at -$55.1 million in 2022, then spiked by 72.69% to -$15.0 million in 2023, then decreased by 21.39% to -$18.3 million in 2024, then decreased by 29.62% to -$30.9 million in 2025.
  • Its Income from Continuing Operations stands at -$30.9 million for Q3 2025, versus -$24.9 million for Q2 2025 and -$20.1 million for Q1 2025.